The stock of CRISPR Therapeutics AG (CRSP) has seen a -1.67% decrease in the past week, with a -25.93% drop in the past month, and a -16.57% decrease in the past quarter. The volatility ratio for the week is 4.94%, and the volatility levels for the past 30 days are at 5.88% for CRSP. The simple moving average for the past 20 days is -13.12% for CRSP’s stock, with a -25.04% simple moving average for the past 200 days.
Is It Worth Investing in CRISPR Therapeutics AG (NASDAQ: CRSP) Right Now?
Moreover, the 36-month beta value for CRSP is 1.71. Analysts have varying opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRSP is 81.36M and currently, short sellers hold a 20.19% of that float. On August 14, 2024, CRSP’s average trading volume was 1.33M shares.
CRSP) stock’s latest price update
CRISPR Therapeutics AG (NASDAQ: CRSP)’s stock price has plunge by -3.61relation to previous closing price of 48.22. Nevertheless, the company has seen a -1.67% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-14 that CRISPR Therapeutics’ stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns.
Analysts’ Opinion of CRSP
Many brokerage firms have already submitted their reports for CRSP stocks, with Needham repeating the rating for CRSP by listing it as a “Buy.” The predicted price for CRSP in the upcoming period, according to Needham is $84 based on the research report published on August 06, 2024 of the current year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $90. The rating they have provided for CRSP stocks is “Buy” according to the report published on August 02nd, 2024.
CRSP Trading at -17.29% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.98% of loss for the given period.
Volatility was left at 5.88%, however, over the last 30 days, the volatility rate increased by 4.94%, as shares sank -23.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -18.60% lower at present.
During the last 5 trading sessions, CRSP fell by -1.59%, which changed the moving average for the period of 200-days by +18.73% in comparison to the 20-day moving average, which settled at $52.80. In addition, CRISPR Therapeutics AG saw -25.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRSP starting from Bruno Julianne, who sale 3,366 shares at the price of $56.09 back on Jun 21 ’24. After this action, Bruno Julianne now owns 6,745 shares of CRISPR Therapeutics AG, valued at $188,799 using the latest closing price.
Kulkarni Samarth, the Chief Executive Officer of CRISPR Therapeutics AG, sale 19,582 shares at $59.91 during a trade that took place back on Apr 15 ’24, which means that Kulkarni Samarth is holding 208,122 shares at $1,173,232 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -1.76 for the present operating margin
- 0.24 for the gross margin
The net margin for CRISPR Therapeutics AG stands at -1.32. The total capital return value is set at -0.16. Equity return is now at value -14.00, with -11.72 for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.53. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -19.93.
Currently, EBITDA for the company is -202.7 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 18.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.73.
Conclusion
To wrap up, the performance of CRISPR Therapeutics AG (CRSP) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
